Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone

被引:1
|
作者
Mannelli, Paolo [1 ]
Douaihy, Antoine B. [2 ]
Zavod, Abigail [3 ]
Legedza, Anna [4 ]
Akerman, Sarah C. [5 ]
Sullivan, Maria A. [5 ,6 ]
机构
[1] Duke Univ, Dept Psychiat & Behav Sci, Med Ctr, 2213 Elba St,Ste 156,DUMC 3074, Durham, NC 27705 USA
[2] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA
[3] Alkermes Inc, Clin Res, Waltham, MA USA
[4] Alkermes Inc, Biostat, Waltham, MA USA
[5] Alkermes Inc, Med Affairs, Waltham, MA USA
[6] Columbia Univ, Dept Psychiat, New York, NY USA
来源
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE | 2021年 / 47卷 / 06期
关键词
Antagonist; maintenance; opioid discontinuation; partial agonist; substance use; INPATIENT;
D O I
10.1080/00952990.2021.1969659
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background Pharmacologic treatment is recommended for many individuals with opioid use disorder (OUD). For patients who select opioid antagonist treatment, effective management of opioid withdrawal symptoms during transition to antagonist treatment requires consideration of the patient experience. Objectives To compare patterns of opioid withdrawal between those withdrawing from untreated opioid use and those withdrawing from buprenorphine. Methods We performed a post hoc, cross-study comparison of the temporal pattern of opioid withdrawal during 1-week induction onto extended-release naltrexone by similar protocols enrolling two participant populations: participants with OUD entering a study with untreated opioid use (N = 378, NCT02537574) or on stable buprenorphine (BUP) treatment (N = 101, NCT02696434). Results The temporal pattern of withdrawal from induction day 1 through day 7 differed between the two participant populations for Clinical Opiate Withdrawal Score (COWS) and Subjective Opiate Withdrawal Score (SOWS): participants with untreated OUD prior to study entry were more likely to experience an earlier relative peak in opioid withdrawal followed by a gradual decline, whereas participants on stable BUP treatment prior to study entry were more likely to experience a relatively later, though still mild, peak opioid withdrawal. The peak COWS was reached at a mean (standard deviation) of 1.9 (1.5) days for participants with untreated OUD and 5.0 (1.5) days for participants on stable BUP. Daily peak cravings were generally higher for participants with untreated OUD than participants on stable BUP. Conclusion Awareness of population-specific variations in the patient experience of opioid withdrawal may help clinicians anticipate the expected course of withdrawal.
引用
收藏
页码:753 / 759
页数:7
相关论文
共 50 条
  • [21] Extended-release naltrexone versus buprenorphine-naloxone to treat opioid use disorder among black adults
    Haeny, Angela M.
    Montgomery, LaTrice
    Burlew, A. Kathleen
    Campbell, Aimee N. C.
    Scodes, Jennifer
    Pavlicova, Martina
    Rotrosen, John
    Nunes, Edward
    ADDICTIVE BEHAVIORS, 2020, 110
  • [22] Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder
    Flam-Ross, Juliet M.
    Marsh, Elizabeth
    Weitz, Michelle
    Savinkina, Alexandra
    Schackman, Bruce R.
    Wang, Jianing
    Madushani, R. W. M. A.
    Morgan, Jake R.
    Barocas, Joshua A.
    Walley, Alexander Y.
    Chrysanthopoulou, Stavroula A.
    Linas, Benjamin P.
    Assoumou, Sabrina A.
    JAMA NETWORK OPEN, 2023, 6 (09) : E2329583
  • [23] Choice of extended release medication for OUD in young adults (buprenorphine or naltrexone): A pilot enhancement of the Youth Opioid Recovery Support (YORS) intervention
    Wenzel, Kevin
    Selby, Victoria
    Wildberger, Jared
    Lavorato, Luciana
    Thomas, Julia
    Fishman, Marc
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2021, 125
  • [24] EFFICACY OF EXTENDED-RELEASE INJECTABLE BUPRENORPHINE FOR PATIENTS WITH DUAL OPIOID AND COCAINE USE DISORDER
    Marsden, John
    Kelleher, Michael
    DRUG AND ALCOHOL DEPENDENCE, 2024, 260
  • [25] Pain Management in Patients With Opioid Use Disorder on Extended-release Buprenorphine: A Case Report
    South, Anna-Maria
    Oller, Devin
    Lofwall, Michelle
    Fanucchi, Laura C.
    JOURNAL OF ADDICTION MEDICINE, 2024, 18 (01) : 86 - 89
  • [26] A Brief Educational Intervention to Increase ED Initiation of Buprenorphine for Opioid Use Disorder (OUD)
    Khatri, Utsha G.
    Lee, Kathleen
    Lin, Theodore
    D'Orazio, Joseph L.
    Patel, Mitesh S.
    Shofer, Frances S.
    Perrone, Jeanmarie
    JOURNAL OF MEDICAL TOXICOLOGY, 2022, 18 (03) : 205 - 213
  • [27] A Brief Educational Intervention to Increase ED Initiation of Buprenorphine for Opioid Use Disorder (OUD)
    Utsha G. Khatri
    Kathleen Lee
    Theodore Lin
    Joseph L. D’Orazio
    Mitesh S. Patel
    Frances S. Shofer
    Jeanmarie Perrone
    Journal of Medical Toxicology, 2022, 18 : 205 - 213
  • [28] Understanding the Partial Agonist: Treating Cancer Pain in Patients with a History of Opioid Use Disorder (OUD) on Buprenorphine
    Weiss, Lara
    Kelly, Lauren
    Bhurjee, Ikwinder
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2023, 65 (05) : E528 - E528
  • [29] Attitudes toward extended-release naltrexone treatment for opioid use disorder among African Americans
    Rigg, Khary K.
    DRUG AND ALCOHOL DEPENDENCE, 2024, 257
  • [30] Patients with Opioid Use Disorder Choosing Treatment with Extended-Release Naltrexone: A 6-Month Naturalistic Study
    Brenna, Ida Halvorsen
    Waleur, Karin Merethe
    Benth, Jurate Saltyte
    Solli, Kristin K.
    Mordal, Jon
    Loberg, Else-Marie
    Weimand, Bente
    Tanum, Lars
    EUROPEAN ADDICTION RESEARCH, 2025, 31 (01) : 1 - 12